Denali Therapeutics Inc (NASDAQ: DNLI) started the day on Thursday, with a price increase of 12.53% at $20.93, before settling in for the price of $18.6 at the close. Taking a more long-term approach, DNLI posted a 52-week range of $10.57-$24.34.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -4.46%. Meanwhile, its Annual Earning per share during the time was -4.46%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -15.23%. This publicly-traded company’s shares outstanding now amounts to $146.63 million, simultaneously with a float of $139.92 million. The organization now has a market capitalization sitting at $3.27 billion.
Denali Therapeutics Inc (DNLI) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Denali Therapeutics Inc’s current insider ownership accounts for 10.40%, in contrast to 89.97% institutional ownership. According to the most recent insider trade that took place on Jan 06 ’26, this organization’s President and CEO sold 35,198 shares at the rate of 16.50, making the entire transaction reach 580,767 in total value, affecting insider ownership by 296,833. Preceding that transaction, on Jan 06 ’26, Company’s COFO and Secretary sold 17,218 for 16.50, making the whole transaction’s value amount to 284,097. This particular insider is now the holder of 282,828 in total.
Denali Therapeutics Inc (DNLI) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.
Denali Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -15.23% and is forecasted to reach -2.82 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -0.10% through the next 5 years, which can be compared against the -4.46% growth it accomplished over the previous five years trading on the market.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Let’s observe the current performance indicators for Denali Therapeutics Inc (DNLI). It’s Quick Ratio in the last reported quarter now stands at 9.79.
In the same vein, DNLI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.91, a figure that is expected to reach -0.74 in the next quarter, and analysts are predicting that it will be -2.82 at the market close of one year from today.
